New antibiotics for ventilator-associated pneumonia

Bassetti, Matteo; Vena, Antonio; Castaldo, Nadia; Righi, Elda; Peghin, Maddalena

doi:10.1097/qco.0000000000000438

Cited by 59 publications

(31 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A combination of other antibiotic agents (e.g., plazomicin, fosfomycin, etc.) [88] or the anti-MRSA agent with ceftazidime-avibactam is plausibly recommended to enforce control of drug-resistant VAP.…”

Section: Special Considerations About Specific Antibiotics For Hap/vapmentioning

confidence: 99%

Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia

Jean

Chang

Wei

et al. 2020

JCM

View full text Add to dashboard Cite

Septicaemia likely results in high case-fatality rates in the present multidrug-resistant (MDR) era. Amongst them are hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), two frequent fatal septicaemic entities amongst hospitalised patients. We reviewed the PubMed database to identify the common organisms implicated in HAP/VAP, to explore the respective risk factors, and to find the appropriate antibiotic choice. Apart from methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, extended-spectrum β-lactamase-producing Enterobacteriaceae spp., MDR or extensively drug-resistant (XDR)-Acinetobacter baumannii complex spp., followed by Stenotrophomonas maltophilia, Chryseobacterium indologenes, and Elizabethkingia meningoseptica are ranked as the top Gram-negative bacteria (GNB) implicated in HAP/VAP. Carbapenem-resistant Enterobacteriaceae notably emerged as an important concern in HAP/VAP. The above-mentioned pathogens have respective risk factors involved in their acquisition. In the present XDR era, tigecycline, colistin, and ceftazidime-avibactam are antibiotics effective against the Klebsiella pneumoniae carbapenemase and oxacillinase producers amongst the Enterobacteriaceae isolates implicated in HAP/VAP. Antibiotic combination regimens are recommended in the treatment of MDR/XDR-P. aeruginosa or A. baumannii complex isolates. Some special patient populations need prolonged courses (>7-day) and/or a combination regimen of antibiotic therapy. Implementation of an antibiotic stewardship policy and the measures recommended by the United States (US) Institute for Healthcare were shown to decrease the incidence rates of HAP/VAP substantially.

show abstract

Section: Special Considerations About Specific Antibiotics For Hap/vapmentioning

confidence: 99%

Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia

Jean

Chang

Wei

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Notably, avibactam is not able to inhibit strains producing metallo-β-lactamases (MBL-Class B), such as the New Delhi metallo-β-lactamase (NDM), Verona integronencoded metallo-β-lactamase (VIM) and Imipenmase (IMP), as well as many of the Class D enzymes, including Acinetobacter OXA carbapenemases. 28 However, in vitro studies suggested a synergistic effect of aztreonam combined with CAZ-AVI for MDR Enterobacteriaceae MBL producers, but this combination unfortunately is not yet commercialized. 29,30 Interestingly, CAZ-AVI has shown highly bactericidal activity in vitro against Mycobacterium avium complex and Mycobacterium tuberculosis, including MDR strains 31,32 (Tables 2 and 3).…”

Section: Caz-avi Mechanism Of Action and Spectrum Of Actionmentioning

confidence: 99%

<p>Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam</p>

Bassetti

Peghin²,

Mesini³

et al. 2020

IDR

Self Cite

View full text Add to dashboard Cite

Antimicrobial resistance poses a substantial threat to global public health. The pursuit of new antibiotics has decreased and very few options have been investigated for the treatment of complicated multidrug-resistant Gram-negative (MDR-GN) infections in adult population and even less in pediatric patients. Ceftazidime-avibactam (CAZ-AVI) is novel cephalosporin/β-lactamase inhibitor (BL-BLI) combination with broad antibacterial spectrum. The aim of this review is to describe the current and future role CAZ-AVI in the pediatric population with suspected or confirmed MDR-GN infections.

show abstract

“…При выделении в качестве возбудителя синегнойной па лочки или БЛРСпродуцирующих энтеробактерий, чув ствительных к цефтолозану/тазобактаму, доступность последнего расширит далеко небогатый на сегодняшний день выбор эффективных АМП [41]. Кроме того, пер спективой ближайшего будущего является регистрация показаний к применению данного препарата для лече ния пациентов с нозокомиальной пневмонией, когда грамотрицательные возбудители становятся доминиру ющими инфекционными агентами [42,43].…”

Section: заключениеunclassified

Ceftolozane/tazobactam – the «new player» in a battle against multiresistant pathogens

Golub

Kozlov

2018

CMAC

View full text Add to dashboard Cite

Цефтолозан/тазобактам-новый комбинированный антимикробный препарат для борьбы с инфек циями, вызванными грамотрицательными микроорганизмами, в т.ч. устойчивыми к широко приме няемым антибиотикам. В обзоре раскрыты особенности действия препарата, приведены данные по клинической и микробиологической эффективности, а также определено его место для терапии пациентов с осложненными интраабдоминальными инфекциями и инфекциями мочевых путей в све те национальных данных по чувствительности их возбудителей.

show abstract

New antibiotics for ventilator-associated pneumonia

Cited by 59 publications

References 45 publications

Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia

Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia

<p>Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam</p>

Ceftolozane/tazobactam – the «new player» in a battle against multiresistant pathogens

Contact Info

Product

Resources

About